House to mark up bill targeting Chinese biotech and genomics companies
The House Oversight Committee will mark up a far-reaching bill on May 15 that, if passed, could force many US biopharma companies to cut ties with WuXi and several other Chinese life sciences...
View ArticleClik here to view.
AbbVie puts $161M into new R&D site in Germany, will add 300 jobs
AbbVie is investing around €150 million ($161 million) into an R&D site at its Rhineland-Palatinate location in Germany which it expects to complete in 2027, the company announced this week. At a...
View ArticleClik here to view.
Senators from both parties introduce menopause research bill
A group of Democratic and Republican senators introduced a bill on Thursday that calls for $275 million toward federal menopause research and awareness efforts over five years. The legislation would...
View ArticleJ&J showcases more bladder cancer results from 'pretzel' drug-device combo
Updated data from a trial of Johnson & Johnson’s experimental “pretzel” showed that more than 80% of bladder cancer patients who got the treatment saw their tumors melt away, building on a readout...
View ArticleNovartis’ radiopharma gambit; Weight loss battle plays out; Spark...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleUPenn and Stanford analysis finds no secondary cancer cases directly due to...
The University of Pennsylvania’s pioneering cell therapy physician Carl June shared new data Monday that showed the risk of secondary cancers following CAR-T therapy was very low. In over 1,500...
View ArticleIllumina takes a step toward spinning off Grail, though keeps option open for...
Illumina prefers to spin off Grail into an independent business rather than sell the cancer diagnostics company, according to a financial document released Monday that describes the Illumina board’s...
View ArticleClik here to view.
Vertex touts Casgevy sickle cell launch as bluebird makes progress with rival...
Vertex said it’s making strong progress bringing its CRISPR Therapeutics-partnered gene therapy to patients after a landmark approval for sickle cell disease in December. Chief operating officer Stuart...
View ArticleMemo Therapeutics completes $49M Series C to develop kidney transplant...
Swiss biotech Memo Therapeutics raised $22 million (CHF 20 million) in a Series C extension to develop an antibody treatment for BK polyomavirus (BKV) infection in kidney transplant recipients, a...
View ArticleFlagship commits $50M to new startup that scours viral proteins for new drugs
In the midst of the Covid-19 pandemic, while most scientists were busy plotting new ways to combat viruses, one startup quietly began a counterintuitive campaign: getting viruses to work for us,...
View ArticleZenas BioPharma closes $200M round to broaden autoimmune potential for lead drug
Lonnie Moulder’s latest biotech has secured some new cash to expand its work in autoimmune diseases. The startup, Zenas BioPharma, closed a $200 million Series C and will use the money to fund clinical...
View ArticleClik here to view.
Arbor acquires Feng Zhang startup for next-gen gene editing enzymes
In the bid to lock up patent rights to a growing suite of gene editing technologies, Arbor Biotechnologies has acquired a small startup founded by MIT scientist and CRISPR pioneer Feng Zhang, the...
View ArticleClik here to view.
As digital health unicorns are pressured to do more with less, Transcarent...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Transcarent’s $126 million Series D round, which in May bumped its valuation to $2.2 billion, stands...
View ArticleClik here to view.
LabCentral helped create 6,300 jobs and 19 IPOs. Amid a slump, demand for lab...
When LabCentral celebrated its 10th anniversary last year, it was a bittersweet moment. The incubator has helped hundreds of biotechs launch and gain their footing. But startups, especially those with...
View ArticleLilly gets June adcomm for Alzheimer's drug donanemab, following earlier delay
Eli Lilly will face questions from a panel of Alzheimer’s experts on June 10, setting up an approval decision for donanemab after a surprise delay by the FDA in early March. The drug will go before the...
View ArticleLykos’ MDMA therapy to go before FDA committee; GSK expands work with BioVersys
Plus, news about Eledon and Travere Therapeutics: Lykos Therapeutics’ MDMA therapy gets an adcomm date: An FDA advisory committee is scheduled to meet June 4 to weigh the benefits and risks of the...
View ArticleFrom the editor: Our final edition of Endpoints MarketingRx
To our MarketingRx readers — Last week, we made the decision to shut down Endpoints MarketingRx. Over the last year, Endpoints News has put more resources into our core biopharma and healthcare...
View ArticleHow insurance upstart Alignment kept medical costs in check while Medicare...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) High medical costs ate away at the profits of big Medicare Advantage insurers CVS Health and Humana in...
View ArticleAntitrust, AI and Alzheimer’s: Join us in New York next week
On May 16 in New York, Endpoints News and the Financial Times are teaming up to host the US Pharma and Biotech Summit. I’ve been deeply involved in planning our interviews and panels, and we have a...
View ArticleClik here to view.
Exclusive: Engineered B cell therapy startup Walking Fish shuts down
Walking Fish Therapeutics, a biotech startup that attempted to create engineered B cell therapies, has shuttered, founder Rusty Williams confirmed to Endpoints News. The South San Francisco biotech...
View Article